MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Company”), a scientific phase pharmaceutical business dedicated to prolonging healthy life expectancy, today announced that the initial client has been enrolled in the Company’s Phase 2 clinical trial of lead candidate MYMD-1, a dental immune regulatory authority drug, as a treatment for postponing aging and also increasing healthy and balanced life-span.
The main endpoint for the Stage 2 double-blind, placebo-controlled medical test is to accomplish a decrease in the flowing levels of (TNF-α), tumor death factor receptor I (TNFRI) and also IL-6. TNF-α and also IL-6 are the proteins in the body that create swelling and help activate the procedure of aging. The secondary steps of the trial will certainly be the security, tolerability, as well as pharmacokinetics in this populace of clients.
” In a Phase 1 medical trial of MYMD-1, we showed the medicine’s statistically significant effectiveness in lowering degrees of TNF-α, a principal in causing pathological aging, in the blood. The FDA has approved TNF-α decrease as the main endpoint for our Phase 2 research, which our company believe placements us well for a successful Phase 2 outcome,” stated Chris Chapman, M.D., President, Director and also Principal Medical Police Officer of MyMD. “The initiation of individual registration in this research study breakthroughs our objective to slow the aging process, prevent loss of muscle cells in aging, limit frailty, and also expand healthy and balanced life-span.”
MyMD has specified that there are no FDA-approved medications for dealing with aging disorders and also expanding healthy life expectancy people, a market anticipated to be a minimum of $600 billion by 20251 according to a major investment financial institution. TNF-α blockers are the most recommended drugs by income, an international market of about $40 billion each year,2 as well as, according to Nature Aging journal,3 a downturn in aging that would certainly boost life expectancy by one year deserves $38 trillion and by one decade is worth $367 trillion.
Along with aging, MYMD-1’s unique activity in regulating the body immune system as well as treating chronic swelling is being developed for the therapy of autoimmune disease, consisting of rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes mellitus, as well as inflammatory bowel illness.
” We mean to start composing procedures for a Stage 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The increasing prevalence of rheumatoid arthritis and other autoimmune and also inflammatory diseases are driving need for TNF inhibitors like MYMD-1, as well as our company believe our by mouth provided medicine with extremely reduced poisoning would certainly be disruptive to the $60 billion market for RA if authorized by the FDA for this sign.”
Rheumatoid joint inflammation influences about 40 million individuals worldwide.4.
Originally developed for autoimmune conditions, MYMD-1’s main objective is to reduce the aging process, avoid sarcopenia as well as frailty, as well as extend healthy life-span. Since it can go across the blood-brain obstacle and gain access to the main nervous system (CNS), MYMD-1 is additionally placed to be a possible therapy for brain-related disorders. Its system of activity and also effectiveness in conditions including numerous sclerosis (MS) and also thyroiditis have actually been studied via cooperations with numerous scholastic institutions. MYMD-1 is also showing pledge in pre-clinical researches as a potential therapy for blog post- COVID-19 complications and as an anti-fibrotic as well as anti-proliferation healing.
MYMD-1 has actually revealed efficiency in pre-clinical researches in regulating the body immune system by performing as a discerning inhibitor of tumor necrosis factor-alpha (TNF-α), a motorist of chronic inflammation. Unlike other treatments, MYMD-1 has actually been shown in these pre-clinical studies to uniquely obstruct TNF-α when it comes to be overactivated in autoimmune illness and also cytokine tornados, yet not block it from doing its typical task of being a very first -responder to any regular kind of modest infection. MYMD-1’s simplicity of dental application is an additional differentiator contrasted to currently available TNF-α blockers, every one of which call for distribution by injection or infusion. No authorized TNF prevention has actually ever been dosed by mouth. In addition, the drug is not immunosuppressive as well as has actually not been revealed to create the severe side effects usual with conventional therapies that treat inflammation.
Regarding MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a medical phase pharmaceutical business dedicated to expanding healthy and balanced life expectancy, is concentrated on establishing two unique restorative platforms that treat the sources of disease as opposed to only resolving the signs. MYMD-1 is a medication platform based upon a scientific phase little molecule that regulates the immune system to control TNF-α, which drives persistent inflammation, and also various other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, rise longevity, and also deal with autoimmune illness as well as COVID-19- associated depression. The Firm’s second medication platform, Supera-CBD, is being established to treat persistent pain, dependency and also epilepsy. Supera-CBD is a novel synthetic by-product of cannabidiol (CBD) and is being created to address and also improve upon the quickly growing CBD market, that includes both FDA accepted medicines as well as CBD products not presently controlled as medications. To learn more, browse through www.mymd.com.